Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers

Drug Metabolism and Disposition

Volumn 31, Issue 1, 2003, Pages 76-87

  Johnson, Kim ^a   Shah, Ajit ^a   Jaw tsai, Sarah ^a   Baxter, James ^a   Prakash, Chandra ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450 2D6; DRUG METABOLITE; ISOENZYME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECOMBINANT ENZYME; TRAXOPRODIL;

ADULT; ARTICLE; BIOTRANSFORMATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; URINARY EXCRETION;

ADOLESCENT; ADULT; CYTOCHROME P-450 CYP2D6; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0037600622     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.1.76     Document Type: Article

References (36)

1. Balant LP and Gex-Fabry M (1994) Dealing with variability during drug development. J Pharm Pharmacol 46 (Suppl 1):439-444.
2. Ball P and Knuppen R (1980) Catecholestrogens (2- and 4-hydroxyestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol 232 (Suppl):1-127.
3. Bolton JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology, Chem Res Toxicol 13:135-160.
4. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, and Rupniak NM (1999) Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology 38:611-623.
5. Bullock MR, Merchant RE, Carmack CA, Doppenberg E, Shah AK, Wilner KD, Ko G, and Williams SA (1999) An open-label study of CP-101, 606 in subjects with a severe traumatic head injury of spontaneous intracerebral hemorrhage. Ann NY Acad Sci 890:51-58.
6. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont ML, Fox CB, Mena EE, et al. (1995) (1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidino)-1-propanol: a potent new neuroprotectant which blocks of N-methyl-D-aspartate responses. J Med Chem 38:3138-3145.
7. Dehl SS and Kupfer D (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27:681-685.
8. Di X, Bullock R, Watson J, Fatouros P, Chenard B, White W, and Corwin F (1997) Effect of CP-101, 606, a novel NR2B subunit antagonist of N-methyl-D-aspartate receptor, on the volume of ischemic brain damage and cytotoxic brain edema after cerebral artery occlusion in the feline brain. Stroke 28:2244-2251.
9. Emons G, Marriam G, Pfeiffer D, Loriaux D, Ball P, and Knuppen R (1987) Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. J Steroid Biochem 28:499-504.
10. Hanioka N, Kimura S, Meyer UA, and Gonzalez FJ (1990) The human CYP2D6 locus associates with a common genetic defect in drug oxidation: a G1934 to a base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47:994-1001.
11. Kivisto KT and Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S.
12. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
13. Lipsett M, Merriam G, Kono S, Brandon D, Pfeiffer D, and Loriaux D (1983) Metabolic clearance of catechol estrogens, in Catechol Estrogens (Merriam G and Lipsett M eds) pp 105-114, Raven Press, New York.
14. 14C]-CP-101, 606. Enantioselective crystalization of a radiochemically racemic mixture. J Label Compd Radiopharm 39:973-985.
15. Meier UT, Kronbach T, and Meyer UA (1985) Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem 151:286-291.
16. Menniti FS, Chenard BL, Collins MA, Ducat MF, Shalaby IA, and White WF (1997) CP-101, 606: a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 331:117-126.
17. Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai S, and White WF (2000) CP-101, 606, an NR2B subunit selective NMDA receptor antagonist inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39:1147-1155.
18. Menniti FS, Shah AK, Williams SA, Wilner KD, White WF, and Chenard BL (1998) CP-101, 606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev 4:307-322.
19. Merchant RE, Bullock MR, Carmack CA, Shah AK, Wilner KD, Ko G, and Williams SA (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101, 606 in patients with a mild or moderate traumatic brain injury. Ann NY Acad Sci 890:42-50.
20. Meyer UA and Zanger UM (1997) Molecular mechanism of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 17:269-296.
21. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1144.
22. Monks TJ, Hanzlik RP, Cohen GM, Ross D, and Graham DG (1992) Contemporary issues in toxicology: quinone chemistry and toxicity. Toxicol Appl Pharmacol 112:2-16.
23. Morgan D, Sandler M, Davies S, Conolly M, Paterson J, and Dolley CT (1969) Metabolic fate of DL-isoprenaline 7-3H in man and dog. Biochem J 114:8P.
24. Nutter LM, Ngo EO, and Abul-Hajj YJ (1991) Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. J Biol Chem 266:16380-16386.
25. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. I. Evidence of its hemoprotein nature. J Biol Chem 239:2370-2378.
26. Penning TM, Burczynski ME, Hung CF, McCoull KD, Palackal NT, and Tsuruda LS (1999) Dihydrodiiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chem res Toxicol 12:1-18.
27. Prakash C, Cui D, and Johnson K (1997a). Biotransformation of a NMDA receptor antagonist, CP-101, 606, in Long-Evans rats: characterization of glucuronide conjugates by mass spectrometry. 8th North American ISSX Meeting; 1997 October 26-30; Hilton Head, SC. International Society for the Study of Xenobiotics, Cabin John, MD.
28. Prakash C, Kamel A, Cui D, Whalen R, Miceli J, and Tweedie D (2000) Identification of the major human liver cytochrome P450 isoform responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49 (Suppl):358-428.
29. Prakash C, Kamel A, Gummerus J, and Wilner K (1997b) Metabolism and excretion of the antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-872.
30. Prakash C and Soliman V (1997) Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in Long-Evans rat. Drug Metab Dispos 25:1288-1297.
31. Shah AK, Friedman DL, Morse TM, Laboy-Goral L, Hinkel CA, Silber M, Apseloff G, and Friedman HL (1998) Evaluation of methods for rapid screening of CYP2D6 status using dextromethorphan as a probe in normal healthy subjects. Pharm Sci 1:S-32.
32. Shah AK, Sanchez CS, Morse TA, and Friedman H (2000) The effect of coadministartion of a CYP2D6 inhibitor on the oral pharmacokinetics (PK) of CP-101, 606 in healthy subjects. 10th North American ISSX Meeting, Indianapolis, IN. International Society for the Study of Xenobiotics, Cabin John, MD.
33. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, and Parkinson A (1987) Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophy 255:27-41.
34. Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti F, and Nagahisha A (1997) Antinociceptive activity of CP-101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharm 122:809-812.
35. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gleboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
36. Tsuchida E, Rice M, and Bullock R (1997) The neuroprotective effect of the forebrain-selective NMDA antagonist CP-101, 606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 14:409-417.